Shamburg News · 8-K filed Oct 21, 2026, 8:07 AM EDT

Voyager Therapeutics Appoints Robin Swartz President; Expected to Succeed Sandrock as CEO

VYGR · Voyager Therapeutics, Inc.

  • Leadership change
  • Material agreement
  • Materiality: high

On October 20, 2026, Voyager Therapeutics' Board appointed Chief Business Officer and Chief Operating Officer Robin Swartz as President, effective immediately. Swartz is expected to succeed Alfred W. Sandrock, Jr. as Chief Executive Officer following anticipated initial acute safety data from the VY1706 Alzheimer's trial in the first quarter of 2027, and Sandrock is expected to remain on the Board. Under her amended and restated employment agreement, Swartz receives a $625,000 annualized base salary, a target bonus of 50% of base salary, and option and RSU grants effective November 1, 2026 covering 318,500 and 68,250 shares, respectively.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 9.01, accession 0001193125-26-427224.

Written from the filing by Shamburg Markets. Figures are as reported by the company.